Searchable abstracts of presentations at key conferences in endocrinology

ea0042p34 | (1) | Androgens2016

Mechanisms of radioresistance in prostate cells

Guggenberger Fabian , Erb Holger , Skvortsova Ira-Ida , Culig Zoran , Santer Frederic R.

Among androgen deprivation therapy (ADT), radiation therapy is an approved treatment either for early stage local PCa, but also for metastatic M1 stage PCa. However, tumour relapse is a frequent event that affects about 80% of patients undergoing prior treatment. There is increasing evidence that the occurrence of cancer stem cells (CSC) may play an important role in therapy resistance, in particular also in radioresistance. However, our knowledge on the mechanisms of radiores...

ea0042p6 | (1) | Androgens2016

The bi-directional interaction of AR and IL6 signalling in the response to enzalutamide in prostate cancer cells

Handle Florian , Erb Holger HH , Luef Birgit , Hoefer Julia , Dietrich Dimo , Parson Walther , Kristiansen Glen , Santer Frederic R , Culig Zoran

Chronic inflammation and high expression of pro-inflammatory cytokines, such as Interleukin-6 (IL6), are well-known risk factors for prostate cancer (PCa). IL6 is known to activate the androgen receptor (AR) and has been implicated in development of castration resistance. Therefore, we wanted to investigate the interaction of AR and IL6 signalling and the effect on anti-androgen treatment. We could confirm IL6 mediated activation of the AR on 3 AR target genes in presence of R...

ea0042p30 | (1) | Androgens2016

Critical Role of Androgen Receptor Level in Prostate Cancer Cell Resistance to New Generation Antiandrogen Enzalutamide

Hoefer Julia , Akbor Mohammady , Handle Florian , Ofer Philipp , Puhr Martin , Parson Walther , Culig Zoran , Klocker Helmut , Heidegger Isabel

Enzalutamide is an androgen receptor (AR) inhibitor approved for therapy of metastatic castration resistant prostate cancer. However, clinical application revealed that 30 to 40% of patients acquire resistance after a short period of treatment. Currently, the molecular mechanisms underlying such insensitivities are not completely understood, partly due to a lack of model systems. In the present study we established three different cellular models of enzalutamide resistance inc...

ea0042p19 | (1) | Androgens2016

The AR/NCOA1 signaling regulates prostate cancer migration by involvement of PRKD1

Luef Birgit , Handle Florian , Kharaishvili Gvantsa , Hager Martina , Rainer Johannes , Janetschek Gunter , Hruby Stephan , Englberger Christine , Bouchal Jan , Santer Frederic R , Culig Zoran

Due to the urgent need for new prostate cancer (PCa) therapies, the role of androgen receptor (AR) interacting proteins should be investigated. In this study we aimed to address whether the AR coactivator nuclear receptor coactivator 1 (NCOA1) is involved in PCa progression. Therefore, we tested the effect of long-term NCOA1 knockdown on processes relevant to metastasis formation. [3H]-thymidine incorporation assays revealed a reduced proliferation rate in ...

ea0042p7 | (1) | Androgens2016

μ-Crystalline as hormone antagonist in prostate cancer

Merkel Olaf , Aksoy Osman , Suzani Martin , Hassler Melanie , Schlangen Karin , Balber Theresa , Mitterhauser Markus , Moazzami Ali , Schlederer Michaela , Turner Suzanne , Egger Gerda , Hormann Gregor , Hacker Markus , Culig Zoran , Pencik Jan , Kenner Lukas

Prostate cancer (PCa) is the most frequent cancer in men in the western world. PCa growth is highly dependent on androgens and androgen ablation is the cornerstone of current therapeutic approaches. μ-Crystalline (CRYM) is the main component of the kangaroohs eye’s lens. CRYM binds thyroid hormone (T3) in a NADPH dependent manner thereby sequestering it from being transcriptionally active in the nucleus. The role of CRYM in prostate cancer is largely unknown. This st...